TrialSignal
Clinical trial intelligence report
Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT01235819-Jul 28, 2026
NCT ID
NCT01235819
Status
COMPLETED
Phase
PHASE4
Sponsor
Command Hospital, India
Executive brief
Investment-Ready Snapshot
Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus is a PHASE4 clinical asset sponsored by Command Hospital, India in Type 1 Diabetes. SEO and diligence focus: Insulin, Sitagliptin, Exenatide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01235819
Indication
Type 1 Diabetes
Modality
small molecule
Target
Insulin, Sitagliptin, Exenatide
Intervention
Insulin, Sitagliptin, Exenatide
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.